{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:28:48Z","timestamp":1794281328756,"version":"4.9.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004462","name":"Consiglio Nazionale delle Ricerche","doi-asserted-by":"publisher","award":["DSB.AD007.247"],"award-info":[{"award-number":["DSB.AD007.247"]}],"id":[{"id":"10.13039\/501100004462","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004462","name":"Consiglio Nazionale delle Ricerche","doi-asserted-by":"publisher","award":["CUP B55F21003380007"],"award-info":[{"award-number":["CUP B55F21003380007"]}],"id":[{"id":"10.13039\/501100004462","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.biopha.2025.118490","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:52:31Z","timestamp":1756367551000},"page":"118490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Trastuzumab cardiotoxicity and drug cardioprotection in healthy and cardiac dysfunction mouse models"],"prefix":"10.1016","volume":"191","author":[{"given":"Serena","family":"L\u2019Abbate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0666-7801","authenticated-orcid":false,"given":"Matilde","family":"Masini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6042-2999","authenticated-orcid":false,"given":"Sabrina","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4249-6775","authenticated-orcid":false,"given":"Francesca","family":"Forini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"De Tata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8064-8311","authenticated-orcid":false,"given":"Claudia","family":"Kusmic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118490_bib1","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk: a compass for future health","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2025.118490_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jaccao.2022.03.004","article-title":"Prevalence of cardiovascular disease in patients with potentially curable malignancies: a national registry dataset analysis","volume":"4","author":"Battisti","year":"2022","journal-title":"JACC CardioOncology"},{"key":"10.1016\/j.biopha.2025.118490_bib3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jaccao.2022.05.001","article-title":"How common is Pre-Existing cardiovascular disease in cancer patients: what do we know? Does it matter?","volume":"4","author":"Mamas","year":"2022","journal-title":"JACC CardioOncology"},{"key":"10.1016\/j.biopha.2025.118490_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","article-title":"Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies","volume":"188","author":"Dempsey","year":"2021","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.biopha.2025.118490_bib5","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.107.690487","article-title":"Role of neuregulin-1\/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure","volume":"116","author":"Lemmens","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2025.118490_bib6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/378386a0","article-title":"Multiple essential functions of neuregulin in development","volume":"378","author":"Meyer","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118490_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2025.118490_bib8","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1073\/pnas.122249299","article-title":"Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy","volume":"99","author":"\u00d6zcelik","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118490_bib9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10549-011-1783-9","article-title":"Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors","volume":"133","author":"Fedele","year":"2012","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.biopha.2025.118490_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079543","article-title":"Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice","volume":"8","author":"ElZarrad","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118490_bib11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.echo.2014.01.014","article-title":"Doxorubicin and trastuzumab regimen induces biventricular failure in mice","volume":"27","author":"Milano","year":"2014","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.biopha.2025.118490_bib12","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.2147\/OTT.S106528","article-title":"Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking","volume":"9","author":"Coppola","year":"2016","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.biopha.2025.118490_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.658790","article-title":"Structural and electrophysiological changes in a model of cardiotoxicity induced by anthracycline combined with trastuzumab","volume":"12","author":"Altomare","year":"2021","journal-title":"Front Physiol."},{"key":"10.1016\/j.biopha.2025.118490_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121207","article-title":"Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis","volume":"312","author":"Min","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2025.118490_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biopha.2017.06.033","article-title":"Targeting proinflammatory cytokines, oxidative stress, TGF-\u03b21 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity","volume":"93","author":"Kabel","year":"2017","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2025.118490_bib16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2025.118490_bib17","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the european hematology association (EHA), the european society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2025.118490_bib18","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study","volume":"175","author":"Lynce","year":"2019","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.biopha.2025.118490_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2019.06.004","article-title":"Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial. In","author":"Leong","year":"2019","journal-title":"JACC CardioOncology"},{"key":"10.1016\/j.biopha.2025.118490_bib20","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1161\/RES.0000000000000473","article-title":"Preclinical models of cancer Therapy-Associated cardiovascular toxicity: a scientific statement from the American heart association","volume":"129","author":"Asnani","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2025.118490_bib21","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HYPERTENSIONAHA.115.06161","article-title":"Inhibition of Galectin-3 pathway prevents Isoproterenol-Induced left ventricular dysfunction and fibrosis in mice","volume":"67","author":"Vergaro","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2025.118490_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132203","article-title":"Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction","volume":"409","author":"Vergaro","year":"2024","journal-title":"Int J. Cardiol."},{"key":"10.1016\/j.biopha.2025.118490_bib23","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1161\/01.CIR.0000142858.44680.27","article-title":"Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice","volume":"110","author":"Garnier","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2025.118490_bib24","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1096\/fj.09-131383","article-title":"Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents","volume":"23","author":"Riccio","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2025.118490_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2018.00038","article-title":"Ranolazine attenuates trastuzumab-induced heart dysfunction by modulating ROS production","volume":"9","author":"Riccio","year":"2018","journal-title":"Front Physiol."},{"key":"10.1016\/j.biopha.2025.118490_bib26","article-title":"Mitochondrial dysfunction in heart failure and its therapeutic implications","volume":"9","author":"Liu","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.biopha.2025.118490_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2022.166618","article-title":"Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy","volume":"1869","author":"Arinno","year":"2023","journal-title":"Biochim Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.biopha.2025.118490_bib28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/cvr\/cvv274","article-title":"Bidirectional cross-regulation between ErbB2 and \u03b2-adrenergic signalling pathways","volume":"109","author":"Sysa-Shah","year":"2016","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.biopha.2025.118490_bib29","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of Chemotherapy-Related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2025.118490_bib30","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2025.118490_bib31","article-title":"Bisoprolol protects myocardium cells against ischemia\/reperfusion injury by attenuating unfolded protein response in rats","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118490_bib32","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2478\/jvetres-2021-0054","article-title":"Protective effects of bisoprolol against cadmium-induced myocardial toxicity through inhibition of oxidative stress and NF-\u03ba\u0392 signalling in rats","volume":"65","author":"Liu","year":"2021","journal-title":"J. Vet. Res"},{"key":"10.1016\/j.biopha.2025.118490_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-020-02564-w","article-title":"Prophylactic, single-drug cardioprotection in a comparative, experimental study of doxorubicin-induced cardiomyopathy","volume":"18","author":"L\u00f3di","year":"2020","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.biopha.2025.118490_bib34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.phrs.2009.05.007","article-title":"Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity","volume":"60","author":"Ibrahim","year":"2009","journal-title":"Pharm. Res"},{"key":"10.1016\/j.biopha.2025.118490_bib35","doi-asserted-by":"crossref","DOI":"10.4103\/ijpvm.IJPVM_322_16","article-title":"Effect of angiotensin-converting enzyme inhibitor on cardiac fibrosis and oxidative stress status in lipopolysaccharide-induced inflammation model in rats","volume":"8","author":"Abareshi","year":"2017","journal-title":"Int J. Prev. Med"},{"key":"10.1016\/j.biopha.2025.118490_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108780","article-title":"Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a\/\u03b2-catenin and Jak2\/Stat3 pathways","volume":"113","author":"Zhang","year":"2019","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2025.118490_bib37","doi-asserted-by":"crossref","first-page":"481","DOI":"10.33549\/physiolres.930057","article-title":"The effect of captopril on nitric oxide formation and on generation of radical forms of mitochondrial respiratory chain compounds in ischemic rat heart","volume":"50","author":"Vav\u0159\u00ednkov\u00e1","year":"2001","journal-title":"Physiol. Res"},{"key":"10.1016\/j.biopha.2025.118490_bib38","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/00004872-200305000-00025","article-title":"Chronic inhibition of nitric oxide synthase induces hypertension and cardiomyocyte mitochondrial and myocardial collagen remodelling in the absence of hypertrophy","volume":"21","author":"Rossi","year":"2003","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2025.118490_bib39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4149\/gpb_2010_02_203","article-title":"Mitochondrial function in heart and kidney of spontaneously hypertensive rats: influence of captopril treatment","volume":"29","author":"Mujko\u0161ov\u00e1","year":"2010","journal-title":"Gen. Physiol. Biophys."},{"key":"10.1016\/j.biopha.2025.118490_bib40","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41598-023-50730-z","article-title":"Melatonin enhances captopril mediated cardioprotective effects and improves mitochondrial dynamics in Male wistar rats with chronic heart failure","volume":"14","author":"El-Sayed","year":"2024","journal-title":"Sci. Rep."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225006845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225006845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:47:01Z","timestamp":1777574821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225006845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":40,"alternative-id":["S0753332225006845"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118490","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trastuzumab cardiotoxicity and drug cardioprotection in healthy and cardiac dysfunction mouse models","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118490"}}